How the opioid superagonist DFNZ challenges pain medicine
A publication in Nature in April 2026 reports that N-desethyl-fluornitrazene (DFNZ), a modified nitazene and µ-opioid receptor (MOR) superagonist, produced potent analgesia in rodents with less respiratory depression, weaker dopamine-linked reward signaling, lower withdrawal burden, and no clear tolerance or MOR downregulation. The study challenges the usual assumption that very high MOR efficacy must inevitably produce the full adverse-effect profile seen with conventional opioids. Opioid pharmacology has long been …
How the opioid superagonist DFNZ challenges pain medicine



![Metrics got you into medicine and are making you unhappy in it [PODCAST]](https://kevinmd.com/wp-content/uploads/maxresdefault-5-190x100.jpg)












